Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
August 02, 2022 at 11:37 am
Share
Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 384.2 million compared to CNY 221.87 million a year ago. Revenue was CNY 387.23 million compared to CNY 225.54 million a year ago. Net income was CNY 18.87 million compared to CNY 7.22 million a year ago. Basic earnings per share from continuing operations was CNY 0.15 compared to CNY 0.07 a year ago. Diluted earnings per share from continuing operations was CNY 0.15 compared to CNY 0.07 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.